Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/5/2025

Hormone Replacement Therapy and Contraception

Application and Administration

  • The transdermal contraceptive patch is applied once weekly for three consecutive weeks, followed by one patch-free week during which withdrawal bleeding typically occurs, and can be placed on the abdomen, upper torso, upper outer arm, or buttocks 1, 2
  • The generic equivalent of the Ortho Evra patch is a transdermal contraceptive patch containing 0.6 mg norelgestromin and 0.75 mg ethinyl estradiol, commonly referred to as the norelgestromin/ethinyl estradiol transdermal system, which measures approximately 1.75 × 1.75 inches 1

Efficacy and Effectiveness

  • Typical use failure rate is similar to combined oral contraceptives at approximately 9% 1, 2
  • Efficacy may be reduced in women weighing more than 198 pounds (90 kg) 2

Safety and Risks

  • Estradiol patches may increase the frequency and severity of attacks in women with hereditary angioedema 3
  • Combined hormonal contraceptives, including patches, may increase attack frequency and severity in women with hereditary angioedema 3
  • There is a potential increased risk of venous thromboembolism compared to 20-35 μg ethinyl estradiol oral contraceptives 1
  • The patch carries a black box warning regarding increased risk of venous thromboembolism compared to some oral contraceptives 1
  • The FDA has identified increased estrogen exposure (1.6 times higher than with low-dose combined oral contraceptives) 1, 2

Side Effects and Application Site Reactions

  • Erythema (redness) occurs in up to 66% of patch users, and breast tenderness and swelling are common side effects, with fluid retention (generally mild but use with caution in patients with heart failure) also being reported 4
  • Side effects are similar to those of combined oral contraceptives, with the addition of application site reactions and potential skin effects (hyperpigmentation, contact dermatitis) 1, 2

Special Populations

  • In transgender women, estradiol patches may cause breast development (desired effect), decreased muscle cross-sectional area, and changes in lipid profiles 5
  • Women with contraindications to estrogen should consider progestin-only alternatives 6